|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
|
IL160406A0
(en)
|
1995-06-15 |
2004-07-25 |
Crucell Holland Bv |
A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20030207346A1
(en)
*
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
ATE299938T1
(de)
|
1997-05-02 |
2005-08-15 |
Genentech Inc |
Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
|
|
US20050164386A1
(en)
*
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
|
US8236561B2
(en)
*
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
US6855544B1
(en)
*
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
|
US7297680B2
(en)
*
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
|
US7192759B1
(en)
*
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7521220B2
(en)
*
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7658924B2
(en)
*
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
ATE542904T1
(de)
*
|
2001-10-29 |
2012-02-15 |
Crucell Holland Bv |
Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
|
|
DK2314629T4
(da)
|
2002-07-18 |
2023-02-06 |
Merus Nv |
Rekombinant produktion af blandinger af antistoffer
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
AU2003296925A1
(en)
*
|
2002-11-01 |
2004-06-07 |
Leucadia Technologies, Inc. |
Displacement sandwich immuno-pcr
|
|
GB0230201D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Retargeting
|
|
SI1583830T1
(sl)
|
2003-01-07 |
2006-12-31 |
Symphogen As |
Postopek za pripravo rekombinantnih poliklonskih proteinov
|
|
US8337841B2
(en)
*
|
2003-01-21 |
2012-12-25 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of screening for antibody light chains
|
|
AU2004240782B2
(en)
*
|
2003-05-23 |
2011-04-21 |
Crucell Holland B.V. |
Production of recombinant IGM in per.C6 cells
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
WO2004106375A1
(en)
*
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
EP1508576A1
(en)
*
|
2003-08-20 |
2005-02-23 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
EP1737971B1
(en)
|
2004-01-20 |
2017-08-16 |
Merus N.V. |
Mixtures of binding proteins
|
|
AU2011218688B2
(en)
*
|
2004-05-27 |
2013-01-10 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing rabies virus and uses thereof
|
|
EP2314620B1
(en)
|
2004-05-27 |
2013-06-05 |
Crucell Holland B.V. |
Method of identifying binding molecules capable of neutralizing rabies virus
|
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
|
US8288109B2
(en)
|
2004-07-20 |
2012-10-16 |
Symphogen A/S |
Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
|
|
EA014182B1
(ru)
|
2004-07-20 |
2010-10-29 |
Симфоген А/С |
КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ
|
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
|
DK1842226T3
(da)
*
|
2004-11-03 |
2010-10-18 |
Iris Molecular Diagnostics Inc |
Homogen analytpåvisning
|
|
EP2302078B1
(en)
*
|
2004-11-03 |
2015-07-15 |
Iris Molecular Diagnostics, Inc. |
Microbubbles for affinity concentration
|
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
PT1876236E
(pt)
*
|
2005-04-08 |
2014-10-22 |
Chugai Pharmaceutical Co Ltd |
Anticorpos para substituição da função do factor de coagulação sanguínea viii
|
|
PL1874821T3
(pl)
|
2005-04-26 |
2013-09-30 |
Trion Pharma Gmbh |
Kombinacja przeciwciał i glikokortykoidów do leczenia raka
|
|
EP1934867A2
(en)
|
2005-08-31 |
2008-06-25 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
|
US20070111237A1
(en)
*
|
2005-09-14 |
2007-05-17 |
Maurizio Zanetti |
Process for identifying antigenized antibodies using ribosome cell free expression system
|
|
KR20140133958A
(ko)
*
|
2005-10-21 |
2014-11-20 |
엘에프비 유에스에이, 인크. |
항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
|
|
AU2012201010B2
(en)
*
|
2005-10-21 |
2015-01-22 |
Genzyme Corporation |
Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
|
|
DE102005054628A1
(de)
*
|
2005-11-16 |
2007-05-24 |
Cevec Pharmaceuticals Gmbh |
Verfahren zur Herstellung von permanenten humanen Zelllinien
|
|
US7850965B2
(en)
|
2005-12-05 |
2010-12-14 |
Symphogen A/S |
Anti-orthopoxvirus recombinant polyclonal antibody
|
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
|
WO2007094472A1
(ja)
*
|
2006-02-17 |
2007-08-23 |
Atsuo Sekiyama |
生体負荷の指標剤および生体負荷の測定方法
|
|
US20090220508A1
(en)
|
2006-03-15 |
2009-09-03 |
Alexion Pharmaceuticals, Inc. |
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
CN104761637B
(zh)
|
2006-03-31 |
2021-10-15 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
|
PE20081216A1
(es)
|
2006-09-01 |
2008-09-04 |
Therapeutic Human Polyclonals Inc |
Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
|
|
US9388235B2
(en)
|
2006-09-05 |
2016-07-12 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for the treatment of antibody mediated neuropathies
|
|
JP5410985B2
(ja)
|
2006-12-05 |
2014-02-05 |
クルセル ホランド ベー ヴェー |
液体抗狂犬病抗体製剤
|
|
BRPI0808551B1
(pt)
|
2007-03-01 |
2022-04-05 |
Symphogen A/S |
Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
|
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
|
US20090068684A1
(en)
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
|
NL1033696C2
(nl)
*
|
2007-04-16 |
2008-10-20 |
Friesland Brands Bv |
Aan melk ontleende antigeen-specifieke antilichamen, werkwijzen voor het bereiden en gebruik ervan.
|
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
|
EP2145902A3
(en)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
|
MX2009012526A
(es)
*
|
2007-05-25 |
2009-12-09 |
Symphogen As |
Metodo para fabricar una proteina policlonal recombinante.
|
|
US8846867B2
(en)
|
2007-06-26 |
2014-09-30 |
The Trustees Of The University Of Pennsylvania |
Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
|
|
ES2595638T3
(es)
|
2007-09-26 |
2017-01-02 |
Chugai Seiyaku Kabushiki Kaisha |
Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
|
|
JP5769968B2
(ja)
|
2007-10-18 |
2015-08-26 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ
|
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
CN103884840A
(zh)
*
|
2008-02-21 |
2014-06-25 |
艾瑞斯国际有限公司 |
早期确定前列腺癌治疗后复发的方法
|
|
EP2098536A1
(en)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation and identification of antigen- or ligand-specific binding proteins
|
|
EP3023502A1
(en)
|
2008-04-10 |
2016-05-25 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
|
NZ588651A
(en)
*
|
2008-04-23 |
2012-04-27 |
Symphogen As |
Methods for manufacturing a polyclonal protein
|
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2726087A1
(en)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2147594B1
(en)
*
|
2008-06-27 |
2013-11-13 |
Merus B.V. |
Antibody producing non-human mammals
|
|
US8148088B2
(en)
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
|
WO2010022736A2
(en)
|
2008-08-29 |
2010-03-04 |
Symphogen A/S |
Recombinant anti-epidermal growth factor receptor antibody compositions
|
|
EP2159291A1
(en)
|
2008-09-01 |
2010-03-03 |
Agendia B.V. |
Means and method for determining tumor cell percentage in a sample
|
|
CN104262483A
(zh)
*
|
2009-01-26 |
2015-01-07 |
根马布股份公司 |
用于生成抗体混合物的方法
|
|
WO2010089387A1
(en)
|
2009-02-09 |
2010-08-12 |
Morphosys Ag |
Production of oligoclonal mixtures of immunoglobulins in single cells
|
|
EP3266795A1
(en)
|
2009-02-12 |
2018-01-10 |
Cell Signaling Technology, Inc. |
Method for detecting a fig-ros fusion polynucleotide
|
|
TWI541021B
(zh)
|
2009-03-05 |
2016-07-11 |
艾伯維有限公司 |
Ｉｌ－１７結合蛋白
|
|
WO2010129304A2
(en)
*
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
MY192182A
(en)
|
2009-06-26 |
2022-08-04 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
DK3622815T3
(da)
|
2009-07-08 |
2023-06-26 |
Kymab Ltd |
Gnavermodeller og terapeutiske molekyler
|
|
BR112012004546A8
(pt)
|
2009-08-29 |
2017-12-05 |
Abbott Lab |
Terapêutica por proteínas ligantes dll4-ligantes
|
|
CN102770456B
(zh)
|
2009-12-04 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
SMT202600080T1
(it)
*
|
2010-02-08 |
2026-03-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
KR101853278B1
(ko)
|
2010-03-02 |
2018-05-02 |
애브비 인코포레이티드 |
치료학적 ｄｌｌ４ 결합 단백질
|
|
KR101860963B1
(ko)
*
|
2010-04-23 |
2018-05-24 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
|
AR081246A1
(es)
|
2010-05-14 |
2012-07-18 |
Abbott Lab |
Proteinas de union a il-1
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
SMT201700023T1
(it)
|
2010-08-02 |
2017-03-08 |
Regeneron Pharma |
Topi che producono proteine leganti vl
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
|
CN103261220B
(zh)
*
|
2010-08-16 |
2016-06-15 |
诺夫免疫股份有限公司 |
用于生成多特异性和多价抗体的方法
|
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
AU2011295715B9
(en)
|
2010-09-03 |
2017-02-23 |
Abbvie Stemcentrx Llc |
Novel modulators and methods of use
|
|
TWI452136B
(zh)
|
2010-11-17 |
2014-09-11 |
中外製藥股份有限公司 |
A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
|
|
PE20141060A1
(es)
|
2010-12-21 |
2014-09-26 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
|
|
MY161859A
(en)
|
2011-01-03 |
2017-05-15 |
Avm Biotechnology Llc |
Personalized production of biologics and method for reprogramming somatic cells
|
|
ME02106B
(me)
|
2011-02-25 |
2015-10-20 |
Regeneron Pharma |
Miševi sa adam6
|
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
HUE047278T2
(hu)
|
2011-08-05 |
2020-04-28 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
LT3485903T
(lt)
|
2011-09-23 |
2023-02-27 |
Mereo Biopharma 5, Inc. |
Vegf/ dll4 surišantys agentai ir jų panaudojimas
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
RU2654567C2
(ru)
|
2011-10-11 |
2018-05-21 |
Дженентек, Инк. |
Улучшенная сборка биспецифических антител
|
|
SG11201401181YA
(en)
|
2011-10-17 |
2014-04-28 |
Regeneron Pharma |
Restricted immunoglobulin heavy chain mice
|
|
HK1200322A1
(en)
|
2011-10-24 |
2015-08-07 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
|
RU2014121043A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
|
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
|
US9221907B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Anti-GPR49 monoclonal antibodies
|
|
US10598653B2
(en)
|
2011-11-01 |
2020-03-24 |
Bionomics Inc. |
Methods of blocking cancer stem cell growth
|
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
|
SG10201605675WA
(en)
|
2011-12-20 |
2016-09-29 |
Regeneron Pharma |
Humanized light chain mice
|
|
US8962315B2
(en)
|
2011-12-22 |
2015-02-24 |
Elwha Llc |
Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
|
|
US10233424B2
(en)
|
2011-12-22 |
2019-03-19 |
Elwha Llc |
Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
|
|
US10745468B2
(en)
|
2011-12-22 |
2020-08-18 |
Kota Biotherapeutics, Llc |
Compositions and methods for modified B cells expressing reassigned biological agents
|
|
US9175072B2
(en)
|
2011-12-22 |
2015-11-03 |
Elwha Llc |
Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
|
|
UY34556A
(es)
|
2011-12-30 |
2013-07-31 |
Abbvie Inc |
Dominio variable dual de inmunoglobulinas y sus usos
|
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
|
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
|
MX353278B
(es)
*
|
2012-03-06 |
2018-01-05 |
Regeneron Pharma |
Raton con cadena ligera comun.
|
|
WO2013138681A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
EP2825036B1
(en)
|
2012-03-16 |
2018-05-02 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
|
EP3539374A1
(en)
|
2012-03-16 |
2019-09-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
PL2838998T3
(pl)
|
2012-04-18 |
2018-04-30 |
Cell Signaling Technology, Inc. |
EGFR i ROS1 w nowotworze
|
|
US9248181B2
(en)
*
|
2012-04-20 |
2016-02-02 |
Merus B.V. |
Methods and means for the production of Ig-like molecules
|
|
AU2013259276B2
(en)
*
|
2012-05-10 |
2018-03-22 |
Bioatla Llc |
Multi-specific monoclonal antibodies
|
|
ME03551B
(me)
|
2012-06-12 |
2020-07-20 |
Regeneron Pharma |
Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
|
CN102851338A
(zh)
|
2012-07-25 |
2013-01-02 |
苏州康宁杰瑞生物科技有限公司 |
利用电荷排斥作用制备同二聚体蛋白混合物的方法
|
|
ES2456823B1
(es)
*
|
2012-09-21 |
2015-01-27 |
Consejo Superior De Investigaciones Científicas (Csic) |
Método de producción de repertorios complejos de moléculas recombinantes
|
|
HUE042040T2
(hu)
*
|
2012-09-27 |
2019-06-28 |
Merus Nv |
Bispecifikus IGG antitestek mint T-sejt kapcsolók
|
|
TW202037609A
(zh)
|
2012-11-01 |
2020-10-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
|
CN110669136A
(zh)
*
|
2012-11-05 |
2020-01-10 |
全药工业株式会社 |
抗体或抗体组合物的制备方法
|
|
WO2014089209A2
(en)
|
2012-12-04 |
2014-06-12 |
Abbvie, Inc. |
Blood-brain barrier (bbb) penetrating dual specific binding proteins
|
|
US9856319B2
(en)
|
2012-12-28 |
2018-01-02 |
Abbvie Inc. |
Monovalent binding proteins
|
|
EP2938634A2
(en)
|
2012-12-28 |
2015-11-04 |
AbbVie Inc. |
Dual specific binding proteins having a receptor sequence
|
|
KR20200024345A
(ko)
|
2013-01-10 |
2020-03-06 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
JP2016505267A
(ja)
*
|
2013-01-15 |
2016-02-25 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アデノウイルスおよびその使用
|
|
MY178882A
(en)
|
2013-02-20 |
2020-10-21 |
Regeneron Pharma |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
HK1218550A1
(zh)
*
|
2013-03-13 |
2017-02-24 |
Regeneron Pharmaceuticals, Inc. |
常見輕鏈小鼠
|
|
CN105209491A
(zh)
|
2013-03-15 |
2015-12-30 |
艾伯维公司 |
针对TNFα的双重特异性结合蛋白
|
|
WO2014144280A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Inc. |
DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
ME03675B
(me)
|
2013-07-05 |
2020-10-20 |
Genmab As |
Humanizovana ili himerna anтi-cd3 antiтela
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
ES2881306T3
(es)
|
2013-09-27 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Método para la producción de heteromultímeros de polipéptidos
|
|
AU2014330922A1
(en)
|
2013-10-01 |
2016-03-03 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CA2926644A1
(en)
|
2013-10-06 |
2015-04-09 |
Abbvie Inc. |
Dual specific binding proteins directed against immune cell receptors and autoantigens
|
|
CA2931978A1
(en)
|
2013-12-02 |
2015-06-11 |
Abbvie Inc. |
Compositions and methods for treating osteoarthritis
|
|
EP3105250B1
(en)
*
|
2014-02-10 |
2020-08-05 |
IGM Biosciences, Inc. |
Iga multi-specific binding molecules
|
|
JP6771385B2
(ja)
|
2014-02-28 |
2020-10-21 |
メルス ナムローゼ フェンノートシャップ |
二重特異性抗体および医薬組成物
|
|
WO2015130173A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus B.V. |
Antibody that binds erbb-2 and erbb-3
|
|
AU2015231025A1
(en)
|
2014-03-21 |
2016-09-15 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
CA3124228C
(en)
|
2014-03-21 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
EP4050026A1
(en)
|
2014-04-01 |
2022-08-31 |
Adimab, LLC |
Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
|
|
PL3560954T3
(pl)
|
2014-04-03 |
2021-12-13 |
Igm Biosciences, Inc. |
Zmodyfikowany łańcuch J
|
|
CA2944649C
(en)
|
2014-04-04 |
2022-06-21 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
|
BR122021009041B1
(pt)
|
2014-05-06 |
2022-11-29 |
Genentech, Inc |
Métodos para a preparação de uma proteína heteromultimérica
|
|
ES2833230T3
(es)
|
2014-05-13 |
2021-06-14 |
Univ Pennsylvania |
Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo
|
|
SMT202000265T1
(it)
|
2014-07-11 |
2020-07-08 |
Genmab As |
Anticorpi che legano axl
|
|
AR101262A1
(es)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
|
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定ｆｖｉｉｉ的反應性之方法
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
RU2715905C2
(ru)
|
2014-10-01 |
2020-03-04 |
МЕДИММЬЮН, ЭлЭлСи |
Способ конъюгации полипептида
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
US10544220B2
(en)
|
2015-01-08 |
2020-01-28 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20
|
|
CN110655582B
(zh)
|
2015-01-08 |
2022-12-16 |
江苏康宁杰瑞生物制药有限公司 |
具有共同轻链的双特异性抗体或抗体混合物
|
|
IL308212A
(en)
|
2015-01-20 |
2024-01-01 |
Igm Biosciences Inc |
Tumor necrosis factor-α receptor binding molecules and their uses
|
|
EP3957738A1
(en)
|
2015-03-04 |
2022-02-23 |
IGM Biosciences, Inc. |
Cd20 binding molecules and uses thereof
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
US9914777B2
(en)
|
2015-07-10 |
2018-03-13 |
Merus N.V. |
Human CD3 binding antibody
|
|
PL3319993T3
(pl)
|
2015-07-10 |
2020-07-27 |
Genmab A/S |
Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
|
|
IL256562B2
(en)
|
2015-07-15 |
2024-07-01 |
Genmab As |
Human CD3 antibodies or chimeras
|
|
WO2017035274A1
(en)
*
|
2015-08-27 |
2017-03-02 |
Crystal Bioscience Inc. |
Transgenic animal for production of antibodies having a common light chain
|
|
EP3355913B1
(en)
|
2015-09-30 |
2024-10-30 |
IGM Biosciences, Inc. |
Binding molecules with modified j-chain
|
|
EP3356401B1
(en)
|
2015-09-30 |
2020-06-24 |
IGM Biosciences, Inc. |
Binding molecules with modified j-chain
|
|
SMT202100230T1
(it)
|
2015-10-23 |
2021-07-12 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Molecole di legame che inibiscono la crescita tumorale
|
|
WO2017110980A1
(ja)
|
2015-12-25 |
2017-06-29 |
中外製薬株式会社 |
増強された活性を有する抗体及びその改変方法
|
|
AU2016381992B2
(en)
|
2015-12-28 |
2024-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of Fc region-containing polypeptide
|
|
CN108495653A
(zh)
|
2016-01-27 |
2018-09-04 |
免疫医疗有限责任公司 |
用于制备具有定义的糖基化模式抗体的方法
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2017161414A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
|
CR20180554A
(es)
|
2016-04-28 |
2019-01-10 |
Chugai Pharmaceutical Co Ltd |
Preparaciones que contienen anticuerpos
|
|
CN109475627B
(zh)
|
2016-05-26 |
2023-01-06 |
齐鲁普吉湾生物治疗公司 |
抗体混合物
|
|
WO2018011421A1
(en)
|
2016-07-14 |
2018-01-18 |
Genmab A/S |
Multispecific antibodies against cd40 and cd137
|
|
US20190185578A1
(en)
|
2016-07-29 |
2019-06-20 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
|
|
PL3509637T3
(pl)
|
2016-09-06 |
2025-03-10 |
Chugai Seiyaku Kabushiki Kaisha |
Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X
|
|
ES2981272T3
(es)
|
2016-09-23 |
2024-10-08 |
Merus Nv |
Moléculas de unión que modulan una actividad biológica expresada por una célula
|
|
US20190276549A1
(en)
|
2016-11-01 |
2019-09-12 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
CA3045161C
(en)
*
|
2016-12-01 |
2024-06-11 |
Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence |
Production of ricin antibodies in plant
|
|
EP3577137A1
(en)
*
|
2017-02-02 |
2019-12-11 |
Merck Patent GmbH |
Preferred pairing of antibody domains
|
|
EP3580233A1
(en)
|
2017-02-10 |
2019-12-18 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
DK3592769T3
(da)
|
2017-03-09 |
2024-08-12 |
Genmab As |
Antistoffer mod pd-l1
|
|
CN110461358A
(zh)
|
2017-03-31 |
2019-11-15 |
公立大学法人奈良县立医科大学 |
可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
|
|
JP7330942B2
(ja)
|
2017-03-31 |
2023-08-22 |
ジェンマブ ホールディング ビー．ブイ． |
二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法
|
|
MX2019011658A
(es)
|
2017-03-31 |
2019-11-18 |
Merus Nv |
Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
|
|
IL269656B2
(en)
|
2017-03-31 |
2024-06-01 |
Merus Nv |
Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
|
|
JP7296891B2
(ja)
|
2017-05-17 |
2023-06-23 |
メルス ナムローゼ フェンノートシャップ |
乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
MX2020000055A
(es)
|
2017-07-06 |
2020-08-06 |
Merus Nv |
Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
|
|
CN118027197A
(zh)
|
2017-07-06 |
2024-05-14 |
美勒斯公司 |
调节由细胞表达的生物活性的抗体
|
|
AU2018296067B2
(en)
|
2017-07-06 |
2021-06-10 |
Merus B.V. |
Binding molecules that modulate a biological activity expressed by a cell
|
|
GB201710984D0
(en)
*
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
SG11202001050PA
(en)
|
2017-08-09 |
2020-03-30 |
Merus Nv |
Antibodies that bind egfr and cmet
|
|
PE20210005A1
(es)
|
2017-09-29 |
2021-01-05 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
|
|
CN119161488A
(zh)
|
2017-11-01 |
2024-12-20 |
中外制药株式会社 |
具有降低的生物活性的抗体变体和同种型
|
|
CN111699003B
(zh)
*
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
US11773171B2
(en)
|
2017-12-19 |
2023-10-03 |
Surrozen Operating, Inc. |
WNT surrogate molecules and uses thereof
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
MA51666A
(fr)
|
2018-01-24 |
2020-12-02 |
Genmab Bv |
Variants polypeptidiques et leurs utilisations
|
|
TWI890481B
(zh)
|
2018-02-09 |
2025-07-11 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
SG11202008399QA
(en)
|
2018-03-12 |
2020-09-29 |
Genmab As |
Antibodies
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CN112105641A
(zh)
*
|
2018-03-19 |
2020-12-18 |
科塔生物治疗有限责任公司 |
用于经修饰的b细胞表达重新分配的生物剂的组合物和方法
|
|
MA52212A
(fr)
|
2018-03-30 |
2021-02-17 |
Merus Nv |
Anticorps multivalent
|
|
MX2020011552A
(es)
|
2018-05-03 |
2020-11-24 |
Genmab Bv |
Combinaciones de variantes de anticuerpos y usos de las mismas.
|
|
EP3810649A1
(en)
|
2018-06-22 |
2021-04-28 |
Genmab A/S |
Method for producing a controlled mixture of two or more different antibodies
|
|
WO2019243636A1
(en)
|
2018-06-22 |
2019-12-26 |
Genmab Holding B.V. |
Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
US20200017600A1
(en)
|
2018-07-13 |
2020-01-16 |
Genmab A/S |
Variants of cd38 antibody and uses thereof
|
|
US20240254252A1
(en)
|
2018-07-13 |
2024-08-01 |
Genmab A/S |
Trogocytosis-mediated therapy using cd38 antibodies
|
|
EP3860715A1
(en)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B.V. |
Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
|
|
CA3118789A1
(en)
|
2018-11-06 |
2020-05-14 |
Genmab A/S |
Antibody formulation
|
|
CA3124688A1
(en)
|
2018-12-31 |
2020-07-09 |
Merus N.V. |
Truncated multivalent multimers
|
|
JP7443376B2
(ja)
|
2018-12-31 |
2024-03-05 |
メルス ナムローゼ フェンノートシャップ |
混合結合ドメイン
|
|
CA3125380A1
(en)
|
2019-02-18 |
2020-08-27 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Genetically modified non-human animals with humanized immunoglobulin locus
|
|
JP7737306B2
(ja)
|
2019-02-21 |
2025-09-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
|
EP3927431A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EP3927746A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
TW202546002A
(zh)
|
2019-03-29 |
2025-12-01 |
荷蘭商美勒斯公司 |
Cd3結合分子
|
|
TWI862565B
(zh)
|
2019-04-04 |
2024-11-21 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
US20220315661A1
(en)
|
2019-05-09 |
2022-10-06 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
AU2020268684C1
(en)
|
2019-05-09 |
2026-04-02 |
Merus B.V. |
Variant domains for multimerizing proteins and separation thereof
|
|
JP6881658B2
(ja)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
TW202118790A
(zh)
|
2019-07-30 |
2021-05-16 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
EP3772518A1
(en)
|
2019-08-07 |
2021-02-10 |
Merus N.V. |
Modified human variable domains
|
|
GB201912008D0
(en)
|
2019-08-21 |
2019-10-02 |
Cambridge Entpr Ltd |
Antibody
|
|
JP2023500701A
(ja)
|
2019-11-06 |
2023-01-10 |
ジェンマブ ビー．ブイ． |
抗体変種の組み合わせおよびその使用
|
|
JP7773466B2
(ja)
|
2019-11-26 |
2025-11-19 |
シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド |
Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質
|
|
CN116199780A
(zh)
|
2019-12-24 |
2023-06-02 |
美勒斯公司 |
TGF-β-RII结合蛋白质
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
US20230272105A1
(en)
|
2020-01-16 |
2023-08-31 |
Genmab A/S |
Formulations of cd38 antibodies and uses thereof
|
|
IL294368A
(en)
|
2020-01-29 |
2022-08-01 |
Merus Nv |
Means and method for modulating mixed effects in immune cells
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
MX2022009936A
(es)
|
2020-03-18 |
2022-09-12 |
Genmab As |
Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4).
|
|
US11707487B2
(en)
|
2020-04-13 |
2023-07-25 |
Affyimmune Therapeutics, Inc. |
EpCAM antibody and CAR-T cells
|
|
CN115843312A
(zh)
|
2020-04-24 |
2023-03-24 |
马伦戈治疗公司 |
结合至t细胞相关癌细胞的多功能性分子及其用途
|
|
MX2022013797A
(es)
|
2020-05-08 |
2022-11-30 |
Genmab As |
Anticuerpos biespecificos contra cd3 y cd20.
|
|
BR112022023697A2
(pt)
|
2020-05-21 |
2022-12-20 |
Merus Nv |
Métodos e meios para a produção de moléculas semelhantes a ig
|
|
JP2023529846A
(ja)
*
|
2020-06-02 |
2023-07-12 |
バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド |
共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
|
|
JP2023534726A
(ja)
|
2020-07-23 |
2023-08-10 |
ジェンマブ ビー．ブイ． |
多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用
|
|
WO2022023559A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
KR20230065256A
(ko)
|
2020-08-06 |
2023-05-11 |
비온테크 에스이 |
코로나바이러스 s 단백질용 결합제
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
KR20230066040A
(ko)
|
2020-09-10 |
2023-05-12 |
젠맵 에이/에스 |
만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체
|
|
US20240034812A1
(en)
|
2020-09-10 |
2024-02-01 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
JP2023547329A
(ja)
|
2020-10-02 |
2023-11-10 |
ジェンマブ エー／エス |
Ｒｏｒ２へと結合することができる抗体ならびにｒｏｒ２およびｃｄ３に結合する二重特異性抗体
|
|
CA3202416A1
(en)
|
2020-12-16 |
2022-06-23 |
Pieter Fokko VAN LOO |
Multispecific antibodies for the treatment of cancer
|
|
MX2023010567A
(es)
|
2021-03-12 |
2023-09-21 |
Genmab As |
Variantes de anticuerpos no activadoras.
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
WO2022234146A1
(en)
|
2021-05-07 |
2022-11-10 |
Genmab A/S |
PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
|
|
BR112023027006A2
(pt)
|
2021-06-21 |
2024-03-12 |
BioNTech SE |
Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
|
|
IL311141A
(en)
|
2021-09-06 |
2024-04-01 |
Genmab As |
Antibodies capable of binding to CD27, their variants and uses thereof
|
|
EP4413039A1
(en)
|
2021-10-08 |
2024-08-14 |
Genmab A/S |
Antibodies binding to cd30 and cd3
|
|
CN118632872A
(zh)
|
2022-01-25 |
2024-09-10 |
美勒斯公司 |
用于治疗癌症的组合疗法
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
EP4522657A1
(en)
|
2022-05-12 |
2025-03-19 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
WO2023218051A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
CA3261603A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
ANTIBODY-DRUG CONJUGATES
|
|
TW202432177A
(zh)
|
2022-10-31 |
2024-08-16 |
丹麥商珍美寶股份有限公司 |
Ｃｄ３８抗體及其用途
|
|
JPWO2024143442A1
(https=)
|
2022-12-27 |
2024-07-04 |
|
|
|
CN116333103B
(zh)
*
|
2023-02-09 |
2025-10-10 |
广州国家实验室 |
抗沙贝病毒属病毒的中和抗体及其制备方法和应用
|
|
AR132290A1
(es)
|
2023-04-05 |
2025-06-11 |
Genmab As |
Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3
|
|
TW202509071A
(zh)
|
2023-05-12 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
能夠與ｏｘ４０結合之抗體、其變異體及其用途
|
|
TW202509077A
(zh)
|
2023-06-30 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
與纖維母細胞活化蛋白α及死亡受體４結合之抗體
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025262641A1
(en)
|
2024-06-19 |
2025-12-26 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
WO2026078443A1
(en)
|
2024-10-11 |
2026-04-16 |
Pheon Therapeutics Ltd. |
Antibody drug conjugates that bind cdcp1 and uses thereof
|